Jaguar completes enrollment in its pivotal phase 3 ontarget trial of crofelemer for prophylaxis of cancer therapy-related diarrhea

Primary endpoint based on patient reported outcomes from study expected in october 2023 with the completion of the pipe financing of unregistered shares and 6-month lock up term, jaguar has agreed, as described below, not to issue additional equity securities before october 22, 2023 - by which point the company expects to have released top line data for the ontarget trial san francisco, ca / accesswire / may 9, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that it has completed enrolling the target number of 256 patients in the company's global, pivotal, phase 3 ontarget clinical trial of crofelemer for prophylaxis of diarrhea in adult cancer patients receiving targeted therapy with or without chemotherapy. "the company's current cash position includes anticipated gross proceeds from a pipe (private investment in public equity) transaction of approximately $1.86 million involving the issuance and sale of approximately 3,425,000 shares of unregistered jaguar common stock and 6,850,000 warrants not exercisable until the later of january 1, 2024 and stockholder approval, that is expected to close on may 9, 2023, subject to customary closing conditions," said lisa conte, jaguar's president and ceo.
JAGX Ratings Summary
JAGX Quant Ranking